At the Department of Urology at Montefiore Medial Center, our prominent physicians and surgeons offer the highest quality care and management of the entire spectrum of urologic disorders and cancers. From minor incontinence issues to advanced cancer complexities, our subspecialists provide the most advanced surgical and non-surgical treatments for each area of urology including: oncology, erectile dysfunction, gynecology, and pediatrics, with exceptional expertise and compassion.
Consistently at the forefront of advanced therapies and treatments, our celebrated surgeons are nationally acclaimed leaders in minimally invasive (laparoscopic) and robotic surgery, as well as the treatment of erectile dysfunction. Dr. Reza Ghavamian, Interim Chairman of the Department of Urology and Director of the Division of Urologic Oncology, is fellowship trained in urologic oncology and has one of the largest laparoscopic and robotic practices in the region. He provides a unique blend of experience in complex open and laparoscopic tumor resections of the kidney, bladder and prostate. All prostate operations and the majority of bladder cancer operations are performed robotically. A fellowship trained endourologist, Dr. David Hoenig garners praise for his expertise in laparoscopy and endourology, treating a variety of conditions such as kidney stone disease through minimally invasive, endoscopic instruments.
Read the Urology Times Article
At Montefiore, patients have peace of mind knowing that our highly experienced physicians and surgeons are experts in all facets of urologic surgical and non-surgical solutions. In order to optimize patients' experience, we ensure that each receives a comprehensive education about his or her condition and we actively promote the continuum of care - before, during, and after treatment. No matter how basic or intricate patients' needs are, our multidisciplinary team helps them return to their quality of life as quickly as possible.
The Department of Urology at Montefiore places great emphasis on advancing the techniques and therapies for treating urologic diseases through a wide spectrum of basic, translational, and clinical studies, such as the comparison of open partial and laparoscopic nephrectomies. Currently we are conducting several prostate and kidney cancer clinical trials and are also investigating how robotic surgery compares to laparoscopic procedures.
We have expanded our research support staff and database of all cancer cases performed in our oncology division in an effort to better analyze our outcomes based on these radical procedures. Because many of these procedures are relatively new, the body of studies comparing them to traditional/open procedures is growing exponentially. Unlike many similar research efforts at other institutions, all of our databases are structured so we can compare and contrast these procedures and their efficacy to the open standard operations performed at the same institution by the same surgeon. We believe this offers a more accurate assessment of results versus comparing outcomes from nationwide studies. This helps us critically assess our own experience so that we can advise patients, not based on literature and other surgeons, but on our years of experience.